The relatively simple and low-cost procedure could empower laboratories in low-resource areas to generate nanobodies against SARS-CoV-2, as well as other viruses.
A trio of faulty genes fail to put the brakes on the immune system’s all-out assault on SARS-CoV-2, leading to the inflammatory overload characteristic of MIS-C.
A diverse immune response hinges on naive B cells mingling with high affinity ones in the late-stage germinal center. Whether that helps or hinders, however, depends on the virus.
